A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)Dan P. Zandberg, Martin J. Edelman, Jeffrey S. Wolf et al.|Cancer Immunology Immunotherapy|2014Cited by 75
inducTION of mage‐A3 and HPV‐16 immunity by Trojan vaccines in patients with head and neck carcinomaCaroline Voskens, Scott E. Strome, Duane A. Sewell et al.|Head & Neck|2012Cited by 67
A phase I dose escalation trial of MAGE-A3 and HPV-16 specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).Dan P. Zandberg, Martin J. Edelman, Sandra Rollins et al.|Journal of Clinical Oncology|2014Cited by 4